SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                   Form 10-Q/A
                                (Amendment No. 1)

(Mark One)
[X]                  QUARTERLY REPORT PURSUANT TO SECTION 13
                     OR 15(d) OF THE SECURITIES EXCHANGE ACT
                                    OF 1934
                For the quarterly period ended September 30, 2003

                                       or

[  ]          TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934
                   For the Transition Period from ____ to ____

                         Commission file number 0-13634

                              MACROCHEM CORPORATION
                              ---------------------
             (Exact name of registrant as specified in its charter)


          Delaware                                          04-2744744
---------------------------------                      -------------------
  (State or Other Jurisdiction                          (I.R.S. Employer
of Incorporation or Organization)                      Identification No.)

            110 Hartwell Avenue, Lexington, Massachusetts 02421-3134
            --------------------------------------------------------
               (Address of principal executive offices, Zip Code)

                                  781-862-4003
                                  ------------
              (Registrant's telephone number, including area code)

     Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports) and (2) has been subject to such
filing requirements for the past 90 days.
Yes     X         No
    ---------        ---------

     Indicate by check mark whether the registrant is an accelerated filer (as
defined in Rule 12b-2 of the Act).
Yes               No     X
    ---------        --------

     Indicate the number of shares outstanding of each of the issuer's classes
of common stock, as of the latest practicable date.

                Class                          Outstanding at November 30, 2003:
-------------------------------------          ---------------------------------
Common Stock, $.01 par value                             32,814,624


<PAGE>


                                EXPLANATORY NOTE

     This Amendment No. 1 on Form 10-Q/A is being filed to amend Management's
Discussion and Analysis of Financial Condition and Results of Operations
contained in Item 2 of Part I.

                              MACROCHEM CORPORATION

                              INDEX TO FORM 10-Q/A
                              --------------------


                                                                     Page Number
                                                                     -----------
PART I     FINANCIAL INFORMATION

Item 2     Management's Discussion and Analysis of
           Financial Condition and Results of Operations                3-8

PART II    OTHER INFORMATION

Item 6     Exhibits and Reports on Form 8-K                             9-10

SIGNATURES                                                               11

EXHIBIT INDEX                                                          12-13


                                       2
<PAGE>

ITEM 2.   MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
          RESULTS OF OPERATIONS

GENERAL
-------

MacroChem's primary business is the development of specialty pharmaceutical
products for commercialization by employing SEPA(R) (Soft Enhancement of
Percutaneous Absorption), its patented drug delivery technology. SEPA compounds,
when properly combined with drugs, provide pharmaceutical formulations (creams,
gels, lacquers, solutions, etc.) that enhance the transdermal delivery of drugs
into the skin or into the bloodstream. The Company is currently developing
investigational new drugs for the treatment of erectile dysfunction
(Topiglan(R)), testosterone deficiency (Opterone(TM)) and fungal infections of
the toenails (EcoNail(TM)). Our technologies are currently in discovery or
developmental stages and must undergo a rigorous regulatory approval process,
which includes extensive preclinical and clinical testing, to demonstrate safety
and efficacy before any resulting product can be marketed. To date, neither the
Food and Drug Administration ("FDA") nor any of its international equivalents
has approved any of our technologies for marketing. The Company currently
derives no significant revenue from product sales, royalties or license fees.
The Company is developing specific SEPA formulations for use with proprietary
and non-proprietary drugs manufactured by other pharmaceutical companies, and
seeks to commercialize these products through the formation of partnerships,
strategic alliances and licensing arrangements with those companies. If the
Company is unable to form any strategic alliances, partnerships or licensing
arrangements, its business may be materially adversely affected. In addition, if
strategic relationships are formed, the Company may not be able to control the
resources and attention that its partners devote to the products.

The Company's results of operations can vary significantly from year to year and
quarter to quarter, and depend, among other factors, on the signing of new
licenses and product development agreements, the timing of revenues recognized
pursuant to license agreements, the achievement of milestones by licensees, the
progress of clinical trials conducted by licensees and the Company, and the
degree of our research, marketing and administrative efforts. The timing of the
Company's revenues may not match the timing of the Company's associated product
development expenses. To date, research and development expenses have generally
exceeded revenues in any particular period and/or fiscal year.

A significant portion of our research and development expenses (including
employee payroll and related benefits, laboratory supplies, travel, dues and
subscriptions, clinical trial costs, temporary help costs, consulting costs and
allocable costs such as occupancy and depreciation) are not tracked by project
as they benefit multiple projects or our drug delivery technologies in general.
For the three months ended September 30, 2003, $482,000 was not specifically
tracked and $205,000 represents costs associated with clinical trials for our
erectile dysfunction product. For the three months ended September 30, 2002,
$791,800 was not specifically tracked and $212,200 represents costs
associated with clinical trials for our erectile dysfunction product. For the
nine months ended September 30, 2003, $1,487,000 was not specifically tracked
and $392,000 represents costs associated with clinical trials for our erectile
dysfunction product. For the nine months ended September 30, 2002, $2,958,200
was not specifically tracked and $245,800 represents costs associated with
clinical trials for our erectile dysfunction product. Each of our research and


                                       3
<PAGE>

development programs are subject to risks and uncertainties, including the
requirement to seek regulatory approval, that are outside of our control.
Moreover, the product candidates identified in these research and development
programs, which are currently in discovery or developmental stages, must
overcome significant technological, manufacturing and marketing challenges
before they can be successfully commercialized. As a result of these risks and
uncertainties, we are unable to predict with any certainty the period in which
material net cash inflows from such projects could be expected to commence or
the completion date of these programs.

These risks and uncertainties also prevent us from estimating with any certainty
the specific timing and future costs of our clinical development programs,
although historical trends at similarly situated companies indicate that
expenses tend to increase in later stages of development. Our failure to obtain
requisite governmental approvals timely or at all will delay or preclude us from
licensing or marketing our products or limit the commercial use of our products,
which could adversely affect our business, financial condition and results of
operations.

CRITICAL ACCOUNTING POLICIES
----------------------------

Note 1 of the consolidated financial statements included within the Company's
Form 10-K for the year ended December 31, 2002, includes a summary of the
significant accounting policies and methods used in the preparation of our
consolidated financial statements. The following is a brief discussion of the
more significant accounting policies and methods used by the Company.

The Company's discussion and analysis of its financial condition and results of
operations are based upon its financial statements, which have been prepared in
accordance with accounting principles generally accepted in the United States of
America. The preparation of these financial statements requires the Company to
make estimates and judgments that affect the reported amounts of assets,
liabilities, revenues and expenses.

The Company believes the following critical accounting policies affect its more
significant judgments and estimates used in the preparation of its financial
statements. As more fully described in the notes to the consolidated financial
statements included in the Company's Annual Report on Form 10-K for the year
ended December 31, 2002, the Company's business seeks to generate revenues
through the development, commercialization and licensing of drug products based
upon the Company's intellectual property. Revenues derived or expected to be
derived from the sale, assignment, transfer, or licensing of patents or other
intellectual property are recognized over various periods based upon the terms
of the relevant agreement. Research and development funding is generally
recognized as revenue at the time the research and development activities are
performed under the terms of the related agreements, when the counter-party is
obligated to pay, and when no future performance obligation exists. Research and
development revenue is billed on a cost reimbursement basis, which includes
direct costs incurred in connection with research activities and an allocation
of certain other costs incurred by the Company. Revenues from the sale,
assignment, transfer, or licensing of patents or other intellectual property are
recognized over various periods based upon the terms of the relevant agreement.

Costs and expenses incurred in connection with pending patent applications are
deferred. Costs related to successful patent applications are amortized over the
estimated useful lives of the patents using the straight-line method.
Accumulated patent costs and deferred patent application costs related to
patents that are considered to have limited future value are charged to
operations.

                                       4
<PAGE>

RESULTS OF OPERATIONS
---------------------

There were no revenues for the three-month periods ended September 30, 2003 and
September 30, 2002. Revenues, consisting primarily of proceeds from the sale of
a patent, were $1,010,000 for the nine-month period ended September 30, 2003
compared to $43,000 in the same period of the prior year. The increase over the
prior year's nine-month period is the result of the Company having obtained a
payment in connection with the sale of a patent.

Research and development expenses decreased $317,000, or 32%, to $687,000 in the
three-month period ended September 30, 2003 from $1,004,000 in the three-month
period ended September 30, 2002. The decrease is primarily attributable to a
reduction in personnel expenses of approximately $274,000 relating to the
reduction of clinical and research staff levels in November of 2002. For the
nine-month period ended September 30, 2003, research and development expenses
decreased $1,325,000, or 41%, to $1,879,000 from $3,204,000 in the same period
of the prior year. The decrease is primarily attributable to a reduction in
personnel expenses of $950,000 relating to the reduction in clinical and
research staff levels in November 2002 and approximately $128,000 more being
spent on clinical trials in the first nine months of 2002 than in 2003. The
level of research and development expenses is highly dependent on the timing and
extent of new and ongoing research performed in our in-house laboratories as
well as outside contract laboratories. Research and development spending is
expected to increase slightly over the remainder of the year as our ongoing
clinical trial of Topiglan progresses and we initiate new clinical trials.

Marketing, general and administrative expenses increased $381,000, or 69%, to
$936,000 in the three months ended September 30, 2003 from $555,000 in the
three-month period ended September 30, 2002. The increase is primarily
attributable to an increase in consulting fees of $120,000 during the three
months ended September 30, 2003 and the reversal of an employee incentive
compensation accrual of $228,000 in the three months ended September 30, 2002.
For the nine-month period ended September 30, 2003, marketing, general and
administrative expenses decreased $339,000, or 12%, to $2,502,000 from
$2,841,000 in the same period in the prior year. The decrease is primarily
attributable to the reduction in staff implemented in November of 2002,
resulting in a savings of approximately $487,000 partially offset by an increase
in consulting fees of $75,000 primarily relating to investor relations and
business development in the nine month period ended September 30, 2003.
Marketing, general and administrative spending is expected to increase slightly
over the remainder of the year due to increased expenses associated with
business development and investor relations activities.

Other income decreased $28,000, or 67%, to $14,000 in the three-month period
ended September 30, 2003 from $42,000 in the three-month period ended September
30, 2002. Other income decreased $111,000, or 69%, to $51,000 in the nine-month
period ended September 30, 2003 from $162,000 in the nine-month period ended
September 30, 2002. The decrease is due to an average lower invested balance of
cash, cash equivalents and short-term investments resulting from funds used in
Company operations and a decrease in overall return rates.

For the reasons described above, net loss increased $81,000, or 5%, to
$1,609,000 in the three-month period ended September 30, 2003 from $1,528,000 in


                                       5
<PAGE>

the three-month period ended September 30, 2002 and decreased $2,555,000, or
43%, to $3,326,000 in the nine-month period ended September 30, 2003 from
$5,881,000 in the same period of the prior year.

LIQUIDITY AND CAPITAL RESOURCES
-------------------------------

Since inception, the primary source of funding for the Company's operations has
been the private and public sale of its securities, and to a lesser extent, the
licensing of its proprietary technology and products, government grants and the
limited sales of patents, products and test materials. During the first nine
months of 2003, the Company received net proceeds from the exercise of stock
options of approximately $99,000 and there were no stock options exercised for
the nine months ended September 30, 2002. Also, the Company recognized revenue
of $1,010,000 for the nine months ended September 30, 2003, primarily from the
sale of U.S. Patent No. 6,495,124 B1 covering antifungal nail lacquers
containing a pentadecalactone drug-absorption excipient. This patent represented
a non-strategic asset not related to the Company's core SEPA technology.
Accordingly, we believe the sale of this patent will not materially adversely
affect the Company's future operations, cash flows and financial position.
During the first nine months of 2002, the Company recognized $43,000 of revenues
from a research grant.

At September 30, 2003, working capital was approximately $8,606,000, compared to
$8,706,000 at December 31, 2002. The decrease in the Company's working capital,
which was partially offset by $3,027,000 (net of issuance costs and before legal
and accounting fees) received from an equity financing in September 2003, was
due primarily to the use of funds for operations and resulted in a lower balance
of cash, cash equivalents and short-term investments. Until such time as the
Company obtains agreements with third-party licensees or partners to provide
funding for the Company's anticipated business activities or the Company is able
to obtain additional funds through the private or public sale of its securities,
the Company's working capital may be utilized primarily to fund its operating
activities.

There were $3,000 of capital expenditures and $69,000 of patent development
costs for the nine months ended September 30, 2003. The Company anticipates
additional capital and patent expenditures of approximately $75,000 for the
remainder of the current year.

On July 10, 2003, the Board of Directors approved retention payments for certain
key employees, including certain executive officers, in order to enhance
retention of those employees. Payments of up to $80,000 and $155,000 in the
aggregate will be paid on January 1, 2004 and July 1, 2004, respectively.

On March 31, 2003, the Company received a notification from Nasdaq indicating
that, as of December 31, 2002, the Company's stockholders' equity did not comply
with the minimum $10,000,000 stockholders' equity requirement for continued
inclusion on The Nasdaq National Market. On May 28, 2003, the Company received a
further notification from Nasdaq indicating that as a result of continued
non-compliance with this rule, the Company's Common Stock would be delisted from
The Nasdaq National Market at the opening of business on June 6, 2003 unless the
Company filed a hearing request with the Nasdaq Listing Qualifications Panel
before the end of business on June 4, 2003.

                                       6
<PAGE>

Following a hearing on July 17, 2003, the Nasdaq Listing Qualifications Panel
notified the Company that the Panel had determined to continue the listing of
our Common Stock on The Nasdaq National Market, provided that we met certain
conditions, including (a) the completion of a $3,000,000 equity financing no
later than September 12, 2003, (b) achieving compliance on or before October 15,
2003 with the minimum $10,000,000 stockholders' equity requirement and (c)
filing a 10-K for the fiscal year ending December 31, 2003 evidencing continued
compliance with such $10,000,000 requirement.

On September 10, 2003, we completed an equity financing which resulted in gross
proceeds of approximately $3,250,000. On September 29, 2003, we received
notification from Nasdaq that this equity financing satisfied the first
condition established by the Nasdaq Listing Qualifications Panel.

On October 14, 2003, the Company filed a Form 8-K with the Securities and
Exchange Commission evidencing $10,107,136 in stockholders' equity as of August
31, 2003. Subsequently, the Company received notification from Nasdaq that this
8-K filing satisfied the second condition established by the Nasdaq Listing
Qualifications Panel and further notifying the Company that the Panel had
determined to continue the listing of our Common Stock on The Nasdaq National
Market, provided that we meet certain additional conditions, including (a)
filing a 10-Q for the quarter ending September 30, 2003 evidencing compliance
with the minimum $10,000,000 stockholders' equity requirement and (b) filing a
10-K for the fiscal year ending December 31, 2003 evidencing continued
compliance with such $10,000,000 requirement.

Because the Company did not have a minimum of $10,000,000 in stockholders'
equity at September 30, 2003, the Nasdaq Listing Qualifications Panel notified
the Company on November 19, 2003 that the listing of our common stock would be
transferred to The Nasdaq SmallCap Market, which has a minimum stockholders'
equity requirement of $2,500,000, effective as of November 24, 2003. Transfer
of the listing of our common stock to The Nasdaq SmallCap Market could affect
our ability to raise additional funds in the future.

The Company's long term capital requirements will depend upon numerous factors,
including the progress of the Company's research and development programs; the
resources that the Company devotes to self-funded clinical testing, proprietary
manufacturing methods and advanced technologies; the ability of the Company to
enter into licensing arrangements or other strategic alliances; the ability of
the Company to manufacture products under those arrangements and the demand for
its products or the products of its licensees or strategic partners if and when
approved for sale by regulatory authorities. In any event, substantial
additional funds may be required before the Company is able to generate revenues
sufficient to support its operations. There is no assurance that the Company
will be able to obtain such additional funds on favorable terms, if at all. The
Company's inability to raise sufficient funds could require it to delay, scale
back or eliminate certain research and development programs.

                                       7
<PAGE>

The Company believes that its existing cash, cash equivalents and short term
investments will be sufficient to meet its operating expenses and capital
expenditure requirements for the next twelve months. The Company's cash
requirements may vary materially from those now planned because of changes in
focus and direction of the Company's research and development programs,
competitive and technical advances, patent developments or other developments.
It is not believed that inflation will have any significant effect on the
results of the Company's operations.

RECENT ACCOUNTING PRONOUNCEMENTS
--------------------------------

In November 2002, the Emerging Issues Task Force ("EITF") issued EITF Issue No.
00-21, "Revenue Arrangements with Multiple Deliverables" ("EITF 00-21"), which
provides guidance on the timing and method of revenue recognition for sales
arrangements that include the delivery of more than one product or service. EITF
00-21 is effective prospectively for arrangements entered into in fiscal periods
beginning after June 15, 2003. The Company's adoption of the provisions of EITF
00-21 had no effect on the Company's results of operations.


                                       8
<PAGE>

PART II - OTHER INFORMATION

ITEM 6.   EXHIBITS AND REPORTS ON FORM 8-K.

(a)  The following is a list of exhibits to this Quarterly Report on Form 10-Q:

     3.1 Certificate of Incorporation as amended, incorporated by reference to
     Exhibit 3a to the Company's Quarterly Report on Form 10-Q for the quarter
     ended September 30, 1997 (File No. 0-13634).

     3.2 Amended and Restated By-Laws of the Company, incorporated by reference
     to Exhibit 5 to the Company's Current Report on Form 8-K dated August 13,
     1999 (File No. 0-13634).

     10.1 Form of Employment Agreement between the Company and Robert J.
     DeLuccia, incorporated by reference to the Company's Quarterly Report on
     Form 10-Q dated September 30, 2003 (File No. 0-13634).

     10.2 MacroChem Corporation Option Certificate reflecting grant by the
     Company to Robert J. DeLuccia, incorporated by reference to the Company's
     Quarterly Report on Form 10-Q dated September 30, 2003 (File No. 0-13634).

     10.3 Form of Retention Agreement between the Company and Bernard R.
     Patriacca, incorporated by reference to the Company's Quarterly Report on
     Form 10-Q dated September 30, 2003 (File No. 0-13634).

     10.4 Form of Retention Agreement between the Company and Melvin A. Snyder,
     incorporated by reference to the Company's Quarterly Report on Form 10-Q
     dated September 30, 2003 (File No. 0-13634).

     10.5 Form of Retention Agreement between the Company and Thomas C.K. Chan,
     incorporated by reference to the Company's Quarterly Report on Form 10-Q
     dated September 30, 2003 (File No. 0-13634).

     10.6 Form of Retention Agreement between the Company and Glenn E. Deegan,
     incorporated by reference to the Company's Quarterly Report on Form 10-Q
     dated September 30, 2003 (File No. 0-13634).

     10.7 Securities Purchase Agreement, dated as of September 10, 2003, by and
     among MacroChem Corporation and the purchasers listed on Schedule A
     thereto, incorporated by reference to Exhibit 10.1 to the Company's Current
     Report on Form 8-K dated September 12, 2003 (File No. 0-13634).

     10.8 Form of Warrant dated as of September 10, 2003, incorporated by
     reference to Exhibit 10.2 to the Company's Current Report on Form 8-K dated
     September 12, 2003 (File No. 0-13634).

                                       9
<PAGE>

     10.9 Registration Rights Agreement, dated as of September 10, 2003, by and
     among MacroChem Corporation and the investors listed on the signature page
     thereto, incorporated by reference to Exhibit 10.3 to the Company's Current
     Report on Form 8-K dated September 12, 2003 (File No. 0-13634).

     31.1 Certification of Principal Executive Officer Pursuant to Section 302
     of the Sarbanes-Oxley Act of 2002.

     31.2 Certification of Principal Financial Officer Pursuant to Section 302
     of the Sarbanes-Oxley Act of 2002.

     32.1 Certification of Principal Executive Officer Pursuant to Section 1350,
     Chapter 63 of Title 18, United States Code, as Adopted Pursuant to Section
     906 of the Sarbanes-Oxley Act of 2002.

     32.2 Certification of Principal Financial Officer Pursuant to Section 1350,
     Chapter 63 of Title 18, United States Code, as Adopted Pursuant to Section
     906 of the Sarbanes-Oxley Act of 2002.

(b)  A report on Form 8-K was filed on September 9, 2003 detailing
communications received from the Nasdaq Listing Qualifications Panel concerning
continued listing of the Company's Common Stock on The Nasdaq National Market.
A report on Form 8-K was filed on September 12, 2003 disclosing the Company's
equity financing obtained on September 10, 2003.


                                       10
<PAGE>

                                   SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, as amended,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.


                           MacroChem Corporation
                           (Registrant)



December 12, 2003          /s/  Robert J. DeLuccia
                           ----------------------------------------------
                           Robert J. DeLuccia
                           President and Chief Executive Officer
                           (Principal Executive Officer)

                           /s/  Bernard R. Patriacca
                           ----------------------------------------------
                           Bernard R. Patriacca
                           Vice President, Chief Financial Officer and Treasurer
                           (Principal Financial Officer)


                                       11
<PAGE>

                                  EXHIBIT INDEX


The following is a list of exhibits to this Quarterly Report on Form 10-Q:

     3.1 Certificate of Incorporation as amended, incorporated by reference to
     Exhibit 3a to the Company's Quarterly Report on Form 10-Q for the quarter
     ended September 30, 1997 (File No. 0-13634).

     3.2 Amended and Restated By-Laws of the Company, incorporated by reference
     to Exhibit 5 to the Company's Current Report on Form 8-K dated August 13,
     1999 (File No. 0-13634).

     10.1 Form of Employment Agreement between the Company and Robert J.
     DeLuccia, incorporated by reference to the Company's Quarterly Report on
     Form 10-Q dated September 30, 2003 (File No. 0-13634).

     10.2 MacroChem Corporation Option Certificate reflecting grant by the
     Company to Robert J. DeLuccia, incorporated by reference to the Company's
     Quarterly Report on Form 10-Q dated September 30, 2003 (File No. 0-13634).

     10.3 Form of Retention Agreement between the Company and Bernard R.
     Patriacca, incorporated by reference to the Company's Quarterly Report on
     Form 10-Q dated September 30, 2003 (File No. 0-13634).

     10.4 Form of Retention Agreement between the Company and Melvin A. Snyder,
     incorporated by reference to the Company's Quarterly Report on Form 10-Q
     dated September 30, 2003 (File No. 0-13634).

     10.5 Form of Retention Agreement between the Company and Thomas C.K. Chan,
     incorporated by reference to the Company's Quarterly Report on Form 10-Q
     dated September 30, 2003 (File No. 0-13634).

     10.6 Form of Retention Agreement between the Company and Glenn E. Deegan,
     incorporated by reference to the Company's Quarterly Report on Form 10-Q
     dated September 30, 2003 (File No. 0-13634).

     10.7 Securities Purchase Agreement, dated as of September 10, 2003, by and
     among MacroChem Corporation and the purchasers listed on Schedule A
     thereto, incorporated by reference to Exhibit 10.1 to the Company's Current
     Report on Form 8-K dated September 12, 2003 (File No. 0-13634).

     10.8 Form of Warrant dated as of September 10, 2003, incorporated by
     reference to Exhibit 10.2 to the Company's Current Report on Form 8-K dated
     September 12, 2003 (File No. 0-13634).

                                       12
<PAGE>

     10.9 Registration Rights Agreement, dated as of September 10, 2003, by and
     among MacroChem Corporation and the investors listed on the signature page
     thereto, incorporated by reference to Exhibit 10.3 to the Company's Current
     Report on Form 8-K dated September 12, 2003 (File No. 0-13634).

     31.1 Certification of Principal Executive Officer Pursuant to Section 302
     of the Sarbanes-Oxley Act of 2002.

     31.2 Certification of Principal Financial Officer Pursuant to Section 302
     of the Sarbanes-Oxley Act of 2002.

     32.1 Certification of Principal Executive Officer Pursuant to Section 1350,
     Chapter 63 of Title 18, United States Code, as Adopted Pursuant to Section
     906 of the Sarbanes-Oxley Act of 2002.

     32.2 Certification of Principal Financial Officer Pursuant to Section 1350,
     Chapter 63 of Title 18, United States Code, as Adopted Pursuant to Section
     906 of the Sarbanes-Oxley Act of 2002.


                                       13